Immune system stimulation via multi-antigen presentation by dendritic cells

Immune system stimulation via multi-antigen presentation by dendritic cells describes a therapeutic strategy or immunological process rather than a single molecular target. Dendritic cells (DCs) are specialized antigen-presenting cells that play a central role in initiating and regulating immune responses by processing and presenting antigens to T cells, thereby linking innate and adaptive immunity[2][6][1]. They capture, process, and display antigen fragments on MHC molecules, and, upon activation, upregulate costimulatory and cytokine signals to drive T cell responses, immune tolerance, or immune activation, depending on context[4][5][8]. Multi-antigen presentation by dendritic cells is central to many immunotherapies, including dendritic cell-based vaccines for cancer, but is not itself a canonical target (such as a receptor or enzyme), and the entry corresponds to a *process* rather than a distinct molecular entity[6]. Properly, targets in this context would be specific dendritic cell receptors or surface molecules (e.g., CD80, CD86, or Toll-like receptors), not the overall process. Note: This entry is not a specific molecular entity or receptor, but rather a description of an immunological function or strategy. This makes the entry incorrect as a canonical drug target and it should be re-expressed using a specific molecular target within the pathway, such as "CD80 (B7-1)", "CD86 (B7-2)", "Toll-like receptor 4", or "MHC class II" molecules[5][2][6].

Other names

Dendritic cell immune stimulationMulti-antigen presentation by dendritic cellsDC-based immune activation

Activation of T cells through MHC-dependent antigen presentation; Induction of adaptive immune response via co-stimulatory molecule upregulation